-
Guohong Hu, a researcher at the Institute of Nutrition and Health, was invited to discuss the frontiers of tumor metastasis research in the journal Cancer Cell
Time of Update: 2022-10-13
With the diversification and precision of tumor treatment strategies, the prognosis of tumor patients has been effectively improved, but distal organ metastasis is still the most important cause of d
-
Nature Sub-Journal: Why Exercise Prevents Cancer? Exercise metabolism of lactic acid, can enhance anti-cancer immunity
Time of Update: 2022-09-30
The study shows that lactic acid can increase the number of tumor-infiltrating CD8+ T cells and enhance anti-tumor immunity, and this finding is expected to be used to develop new strategies to enhance the anti-tumor effect of cancer immunotherapy.
-
【Nature】New report on cancer: Nearly 50% of global cancer deaths can be avoided
Time of Update: 2022-09-07
This article is original from Translational Medicine Network, please indicate the source for reprinting Author: SophiaIntroduction: Nearly 50% of cancers worldwide are caused by preventable risks, suc
-
Express prolongs the life of patients with advanced breast cancer by nearly 16 months, and the long-term clinical results of Novartis CDK4/6 inhibitor are positive
Time of Update: 2022-05-27
▎WuXi AppTec Content Team Editor Today, Novartis announced that its CDK4/6 inhibitor Kisqali (ribociclib) in combination with fulvestrant as first-line therapy in postmenopausal patients with HR+/HER2- advanced or metastatic breast cancer In the phase 3 clinical trial of fulvestrant, the overall survival of patients was extended by nearly 16 months .
-
The first
Time of Update: 2022-04-28
OlympiA trial results have shown that, The identification of BRCA1/2 mutations in women with high-risk disease gives them an additional option for treatment with olaparib, which reduces the risk of recurrence and improves survival in these breast cancer patients .
-
Br J Cancer: Effects of BRAF, KRAS and MSI on cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with metastatic colorectal cancer (mCRC) with peritoneal
Time of Update: 2022-04-23
Metastatic with BRAF (mutBRAF) or KRAS mutation (mutKRAS)Colorectal cancer (mCRC) patients have poor prognosis after liver or lung surgery, while the prognostic role of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal metastases (PM) is unclear .
-
Express complete remission rate of 83%, positive early clinical results of non-viral gene therapy for bladder cancer
Time of Update: 2022-03-09
▎WuXi AppTec content team editor enGene announced today that EG-70, an innovative non-viral gene therapy for local administration in mucosal tissue based on its proprietary technology platform, is used in the treatment of high-grade non-muscle infiltrates unresponsive to Bacille Calmette-Guerin (BCG) Positive results from a phase 1/2 clinical trial in patients with meningococcal bladder cancer (NMIBC) .
-
Clin Cancer Res: The relationship between the neutrophil/lymphocyte ratio (NLR) and the efficacy of avelumab combined with axitinib or sunitinib in the treatment of advanced renal cell carcinoma (RCC
Time of Update: 2021-12-04
SunitinibThrough the analysis of the JAVELIN Renal 101 clinical study (NCT02684006), the relationship between baseline NLR and progression-free survival (PFS) and overall survival (OS) in the avelumab combined with axitinib or sunitinib group was analyzed Retrospective analysis .
-
China's original third-generation EGFR-TKI in the treatment of lung cancer highlights its unlimited potential
Time of Update: 2021-09-30
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) drugs have completely changed the treatment pattern of advanced non-small cell lung cancer (NSCLC) with EGFR sensitive mutations, and the survival time (OS) of patients has also been significantly prolonged The median OS has been extended from about 12 months in the chemotherapy era to 38.
-
HPV vaccine also has the effect of preventing male HPV infection
Time of Update: 2021-09-18
Professor Qiao Youlin introduced that the quadrivalent HPV vaccine has been approved for immunization in 135 countries or regions around the world, of which 110 countries or regions have been approved for female and male vaccination .
-
Br J Cancer: Correlation analysis between targeted RNAseq detection of breast cancer circulating tumor cells CTC and bone metastasis
Time of Update: 2021-07-27
CTC is a suitable biological source for the detection of disease metastasis research through targeted RNAseq, and may be applied in large-scale prospective studies in the future .
-
Johnson & Johnson abandons Erleada, Zytiga prostate cancer combination therapy regulatory application
Time of Update: 2021-05-23
CompilationFan DongdongAfter failing to reach the secondary endpoint of the key Phase III trial, Johnson & Johnson said it will not seek a regulatory application for the prostate cancer drug combination Erleada and Zytiga in the future.
-
Why do women get more thyroid disease
Time of Update: 2021-05-22
Women with insufficient thyroid reserves (for example, due to iodine deficiency or autoimmune diseases), may not be able to fully meet their thyroid hormone requirements during pregnancy, leading to an increase in TSH.
-
WHO officials and Chinese experts: Get HPV vaccine as soon as possible
Time of Update: 2021-05-07
" During the "World Immunization Week", officials from the World Health Organization's representative office in China and Chinese medical experts participated in a live broadcast of health science popularization in China, calling on the public to pay attention to immunization, especially for young women aged 9 to 14 years old to be vaccinated with human papilloma Virus (HPV) vaccine to strengthen cervical cancer prevention.
-
The key role of intestinal microethics in inflammatory-driven colorectal cancer has been revealed
Time of Update: 2021-01-06
, Gastroenterology published online the latest research results obtained by Qiu Fuming, a professor at Zhejiang University's Second Hospital and Zhejiang Cancer Micro-Environment and Immunotherapy Key Laboratory, in cooperation with Huang Jian's team, revealing the important role of bacteriologic-immune interoperability in the occurrence of enteritis-related tumors.
